MarketAlert – Real-Time Market & Crypto News, Analysis & AlertsMarketAlert – Real-Time Market & Crypto News, Analysis & Alerts
Font ResizerAa
  • Crypto News
    • Altcoins
    • Bitcoin
    • Blockchain
    • DeFi
    • Ethereum
    • NFTs
    • Press Releases
    • Latest News
  • Blockchain Technology
    • Blockchain Developments
    • Blockchain Security
    • Layer 2 Solutions
    • Smart Contracts
  • Interviews
    • Crypto Investor Interviews
    • Developer Interviews
    • Founder Interviews
    • Industry Leader Insights
  • Regulations & Policies
    • Country-Specific Regulations
    • Crypto Taxation
    • Global Regulations
    • Government Policies
  • Learn
    • Crypto for Beginners
    • DeFi Guides
    • NFT Guides
    • Staking Guides
    • Trading Strategies
  • Research & Analysis
    • Blockchain Research
    • Coin Research
    • DeFi Research
    • Market Analysis
    • Regulation Reports
Reading: Prognica Labs and NextGen Immuno Therapeutics announce strategic partnership to accelerate AI-driven precision immunology
Share
Font ResizerAa
MarketAlert – Real-Time Market & Crypto News, Analysis & AlertsMarketAlert – Real-Time Market & Crypto News, Analysis & Alerts
Search
  • Crypto News
    • Altcoins
    • Bitcoin
    • Blockchain
    • DeFi
    • Ethereum
    • NFTs
    • Press Releases
    • Latest News
  • Blockchain Technology
    • Blockchain Developments
    • Blockchain Security
    • Layer 2 Solutions
    • Smart Contracts
  • Interviews
    • Crypto Investor Interviews
    • Developer Interviews
    • Founder Interviews
    • Industry Leader Insights
  • Regulations & Policies
    • Country-Specific Regulations
    • Crypto Taxation
    • Global Regulations
    • Government Policies
  • Learn
    • Crypto for Beginners
    • DeFi Guides
    • NFT Guides
    • Staking Guides
    • Trading Strategies
  • Research & Analysis
    • Blockchain Research
    • Coin Research
    • DeFi Research
    • Market Analysis
    • Regulation Reports
Have an existing account? Sign In
Follow US
© Market Alert News. All Rights Reserved.
  • bitcoinBitcoin(BTC)$71,091.003.92%
  • ethereumEthereum(ETH)$2,200.215.49%
  • tetherTether(USDT)$1.000.01%
  • rippleXRP(XRP)$1.353.44%
  • binancecoinBNB(BNB)$603.27-0.02%
  • usd-coinUSDC(USDC)$1.000.00%
  • solanaSolana(SOL)$82.903.59%
  • tronTRON(TRX)$0.3178621.19%
  • Figure HelocFigure Heloc(FIGR_HELOC)$1.03-0.10%
  • dogecoinDogecoin(DOGE)$0.0930822.19%
Press Releases

Prognica Labs and NextGen Immuno Therapeutics announce strategic partnership to accelerate AI-driven precision immunology

Last updated: February 17, 2026 4:45 pm
Published: 2 months ago
Share

Dubai, UAE / Vienna, Austria – Prognica Labs, an AI-driven life sciences and drug discovery company, and NextGen Immuno Therapeutics (NGIT), a precision immunology and translational HealthTech innovator, today announced a strategic partnership to jointly advance AI-powered immune diagnostics, personalized medicine, and real-world data-driven healthcare solutions across high-growth markets including the GCC, India, and the United States.

The partnership will focus on joint marketing, market access, data acquisition, collaborative research, public health initiatives, and government healthcare projects. By integrating Prognica’s AI and health analytics capabilities with NGIT’s clinically validated precision immunology platform, the alliance aims to deliver scalable precision diagnostics solutions for oncology, transplant medicine, autoimmune disorders, and immune-related diseases.

Addressing Rapidly Growing Global Healthcare Markets

Healthcare systems in the GCC, India, and the USA are undergoing transformative growth driven by increasing chronic disease prevalence, rising treatment demand, and adoption of advanced therapies.

Immunotherapy Market Expansion: The global immunotherapy drugs market is projected to grow from approximately USD 270 billion in 2024 to over USD 1.4 trillion by 2034, reflecting an annualized growth trajectory above 18% driven by innovations in oncology, immune checkpoint inhibitors, and cell therapies. [1] India Market Growth: India’s cancer immunotherapy market reached USD 4 billion in 2024 and is forecast to exceed USD 9.9 billion by 2033, representing sustained double-digit growth. [2] GCC Healthcare Analytics & Data Market: The GCC clinical data analytics market is estimated to grow from USD 115.85 million in 2024 to USD 315 million by 2035, underlining the regional demand for data-driven healthcare insights. [3]

These trends coincide with increasing adoption of real-world evidence solutions, currently a USD 2.5 billion market in the GCC reflecting demand for data to support improved clinical, regulatory and outcomes decisions. [3]

Khalid Shaikh, Founder & CEO, Prognica Labs, said:

“The future of drug discovery lies in precision, not probability. This partnership bridges translational immunology with AI-powered decision systems. In markets like GCC, India, and the United States, where oncology burden is rising sharply, we are building not just a diagnostic solution – but an ecosystem for early detection, patient stratification, and cost-efficient care delivery.”

Transforming Immune Foresight into Actionable Intelligence

Nextgen Immuno Therapeutics has developed an AI-powered immune profiling platform that converts blood samples into patient-specific insight reports, enabling:

Early risk prediction Precise diagnosis Treatment stratification Immune monitoring Personalized therapy guidance

Prognica Labs will enhance this capability through:

AI-driven data harmonization and predictive modeling Real-world evidence (RWE) generation Health systems integration Market access execution Government and institutional project deployment

Together, the companies aim to accelerate adoption of precision immune diagnostics in hospital networks, cancer centers, transplant centers, and public health programs.

Dr. Ram Vinay Pandey, Founder & CEO, Nextgen Immuno Therapeutics, added:

“Immune profiling is the missing layer in personalized medicine. Our platform translates complex immunological signals into clinically actionable insights. By partnering with Prognica Labs, we are accelerating our mission to move from isolated clinical pilots to scalable global deployment – bringing immune foresight to medicine before it’s too late.”

Impact on Healthcare and Pharma Markets

GCC:

GCC countries are rapidly investing in healthcare modernization and data capabilities. AI-powered healthcare analytics markets in the GCC already top USD 1.2 billion, indicating strong regional demand for predictive and precision technologies. [3]

India:

India’s pharmaceutical industry, a global powerhouse valued at approximately USD 50 billion and projected to exceed USD 130 billion by 2030, is well positioned to adopt collaborative solutions across research, clinical trials, and treatment delivery. [4]

USA:

The United States remains the largest market for immunotherapy innovations and precision treatments, driving continued investments in oncology and real-world evidence solutions as drug developers seek accelerated approvals and expanded treatment paradigms. [1]

The partnership will provide a platform for comprehensive insights that improve patient outcomes, optimize clinical trial design, and expand commercial viability of advanced therapeutics and diagnostics.

Dr. Sujay Patil, Chief Scientific Officer, Prognica Labs, commented:

“From a scientific standpoint, integrating immune profiling with advanced AI analytics represents a paradigm shift in how we approach oncology and immune-mediated diseases. Immune signatures provide early biological signals long before clinical deterioration becomes evident. By combining high-dimensional immunological data with predictive modeling, we can improve patient stratification, reduce therapeutic trial-and-error, and generate real-world evidence that strengthens both clinical decision-making and regulatory confidence.”

About Prognica Labs

Prognica Labs a Dubai-based AI-driven biotech company redefining how drug assets are discovered, evaluated, and advanced. Prognica is building a lean, next-generation alternative to traditional pharma R&D – powered by a fully integrated stack of AI agents that automate scientific diligence, in-silico validation, clinical feasibility modeling, and deal structuring, transforming drug development by dramatically reducing time, cost, and risk, turning hidden opportunities into breakthrough therapies for patients.

http://www.prognica.com

About Nextgen Immuno Therapeutics

Nextgen Immuno Therapeutics is a precision immunology HealthTech company developing AI-powered diagnostics solutions for cancer, transplant medicine, autoimmune diseases, and immune-related conditions. Its platform transforms blood-based immune data into personalized clinical insights to guide early diagnosis and targeted therapy.

http://www.nextgenimmuno.com

References:

[1] https://www.biospace.com/press-releases/immunotherapy-drugs-market-size-to-set-to-reach-usd-270-4-billion-by-2034

[2] https://www.imarcgroup.com/india-cancer-immunotherapy-market

[3] https://www.kenresearch.com/gcc-real-world-evidence-solutions-market

[4] https://www.expresspharma.in/pharmalytica-2024-charting-indias-pharmas-path-to-usd-130-billion-by-2030-from-the-powerhouse-hub-of-hyderabad

Read more on Zawya.com

This news is powered by Zawya.com Zawya.com

Share this:

  • Share on X (Opens in new window) X
  • Share on Facebook (Opens in new window) Facebook

Like this:

Like Loading...

Related

EchoStar’s SATS Stock Tests Investor Patience as Wall Street Weighs Dish Merger Payoff
Congressional leaders leave White House meeting without deal to avoid government shutdown
Nemetschek SE / DE0006452907
‘Charlotte’s Web’ brings disputed ICE sightings to Rowan – Salisbury Post
Evotec SE / DE0005664809

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Email Copy Link Print
Previous Article EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Next Article q.beyond AG / DE0005137004
© Market Alert News. All Rights Reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Prove your humanity


Lost your password?

%d